IP Library Granted Patent US 10,962,541
Granted Patent B2
US 10,962,541 · App. 16/270,306 · Granted Mar 30, 2021

Activated GTPase-based assays and kits for the diagnosis of sepsis and other infections

Inventors: Tione Buranda (Albuquerque, NM); Jacob Ongudi Agola (Albuquerque, NM); Soumik BasuRay (Dallas, TX); Scarlett Swanson (Albuquerque, NM); Angela Wandinger-Ness (Albuquerque, NM); Peter C. Simons (Albuquerque, NM); Virginie Bondu (Albuquerque, NM)
Assignee: UNM Rainforest Innovations
G01N33/573G01N33/86G01N2333/914G01N2800/224G01N2800/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,962,541
App. No.
16/270,306
Granted
Mar 30, 2021
Kind
B2
Abstract

In one embodiment, the invention provides a method of diagnosing sepsis or a virus-related infection (often a viral hemorrhagic fever infection) in a subject by detecting and measuring the level of a set of sepsis and virus infection-associated-GTPase biomarkers in a sample obtained from the subject using multiplexed flow cytometry. Related kits are also provided. In a preferred embodiment, the invention provides point of care diagnostic methods for determining an early stage sepsis or the severity of a virus infection, especially in a hospital or other setting.

Claims (24)

1. A kit comprising:

(a) a population of beads which have two or more sizes, which are labeled with a first fluorophore having a single wavelength and a plurality of intensity levels and which are covalently coupled to a plurality of effector proteins which bind to cognate, infection-associated-guanosine triphosphate hydrolases (GTPases) to form effector protein-infection-associated-GTPase conjugates, wherein said GTPases are ras-related C3 botulinum toxin substrate 1 (Rac1) and Ras-related protein 1 (Rap 1) and said effector proteins which bind to Rac is 1 are selected from the group consisting of p21 activated kinase 1 rho binding domain (PAK-1 RBD), steroid receptor RNA activator 1 (Sra1), insulin receptor tyrosine kinase substrate p58/53 (IRSp58/53), p21 activated kinase 1 (PAK1), p21 activated kinase 2 (PAK2), p21 activated kinase 3 (PAK3) and mixtures thereof and said effector protein which binds to Rap1 is ra1 guanine nucleotide dissociation stimulator rho binding domain (Ra1GDS-RBD);

(b) GTPase-specific antibodies which bind to said effector protein-infection-associated-GTPase conjugates formed on the beads;

(c) detector antibodies which are specific to the GTPase-specific antibodies and which are labeled with a second fluorophore having a wavelength (color) which is different from that of the first fluorophore; and

(d) optionally, instructions with respect to the use of the beads, GTPase-specific antibodies and detector antibodies in a flow cytometry assay for detecting the existence or absence of sepsis in a patient or subject in need.

2. The kit of claim 1 , wherein:

(a) the effector proteins are PAK-1 RBD and RalGDS-RBD (a; and

(b) the first fluorophore is a red fluorophore and the second fluorophore is a green fluorophore.

3. The kit of claim 2 , wherein said red fluorophore is a red fluorescent dye and the green fluorophore is a green fluorescent dye.

4. The kit of claim 1 , wherein the first fluorophore is a fluorescent dye and the second fluorophore is a fluorescent dye.

5. The kit of claim 1 , wherein:

(a) the population of beads is defined by distinct sub-sizes, each of which conducts a unique assay; and

(b) the beads are internally covalently coupled to red and infrared fluorophores with different intensities.

6. The kit of claim 1 , wherein the beads are microbeads.

7. The kit of claim 1 , wherein the kit contains at least 10,000 beads conjugated to said effector protein.

8. The kit of claim 1 , wherein the beads are defined by at least two distinct sub-sizes.

9. The kit of claim 1 , wherein the kit can be used in conjunction with a multiplex flow cytometry assay which processes 96 or 384 well-plates.

10. The kit of claim 1 , wherein the kit comprises a positive or negative control.

11. The kit of claim 1 , wherein said flow cytometry assay is a multiplex flow cytometry assay.

12. A kit comprising:

(a) a population of beads which have two or more sizes, which are labeled with a first fluorophore having a single wavelength and a plurality of intensity levels and which are covalently coupled to a plurality of effector proteins which bind to cognate, infection-associated-guanosine triphosphate hydrolases (GTPases) to form effector protein-infection-associated-GTPase conjugates, wherein said GTPases are ras-related C3 botulinum toxin substrate 1 (Rac1) and Ras-related protein 1 (Rap 1) and said effector protein which binds to Rac 1 is p21 activated kinase 1 rho binding domain (PAK-1 RBD) and said effector protein which binds to Rap1 is ra1 guanine nucleotide dissociation stimulator rho binding domain (Ra1GDS-RBD);

(b) GTPase-specific antibodies which bind to said effector protein-infection-associated-GTPase conjugates formed on the beads;

(c) detector antibodies which are specific to the GTPase-specific antibodies and which are labeled with a second fluorophore having a wavelength (color) which is different from that of the first fluorophore; and

(d) instructions with respect to the use of the beads, GTPase-specific antibodies and detector antibodies in a multiplexed flow cytometry assay for detecting the existence or absence of sepsis in a patient or subject in need.

Assignments (1)
CHANGE OF NAME Recorded Feb 17, 2021
From: STC.UNM
To: UNM RAINFOREST INNOVATIONS
Reel/Frame 055294/0291 →
Continuity (3)
Division 14626536 · Feb 19, 2015
Provisional Application 61941604 · Feb 19, 2014
Related Publication 20190242897A1 · Aug 8, 2019